• Something wrong with this record ?

Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase

K. Hlozkova, M. Vasylkivska, A. Boufersaoui, B. Marzullo, M. Kolarik, N. Alquezar-Artieda, M. Shaikh, NF. Alaei, M. Zaliova, M. Zwyrtkova, V. Bakardijeva-Mihaylova, M. Alberich-Jorda, J. Trka, DA. Tennant, J. Starkova

. 2024 ; 605 (-) : 217242. [pub] 20240911

Language English Country Ireland

Document type Journal Article

Tumor cells often adapt to amino acid deprivation through metabolic rewiring, compensating for the loss with alternative amino acids/substrates. We have described such a scenario in leukemic cells treated with L-asparaginase (ASNase). Clinical effect of ASNase is based on nutrient stress achieved by its dual enzymatic action which leads to depletion of asparagine and glutamine and is accompanied with elevated aspartate and glutamate concentrations in serum of acute lymphoblastic leukemia patients. We showed that in these limited conditions glutamate uptake compensates for the loss of glutamine availability. Extracellular glutamate flux detection confirms its integration into the TCA cycle and its participation in nucleotide and glutathione synthesis. Importantly, it is glutamate-driven de novo synthesis of glutathione which is the essential metabolic pathway necessary for glutamate's pro-survival effect. In vivo findings support this effect by showing that inhibition of glutamate transporters enhances the therapeutic effect of ASNase. In summary, ASNase induces elevated extracellular glutamate levels under nutrient stress, which leads to a rewiring of intracellular glutamate metabolism and has a negative impact on ASNase treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003372
003      
CZ-PrNML
005      
20250206104313.0
007      
ta
008      
250121e20240911ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.canlet.2024.217242 $2 doi
035    __
$a (PubMed)39270769
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Hlozkova, Katerina $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic. Electronic address: katerina.hlozkova@lfmotol.cuni.cz
245    10
$a Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase / $c K. Hlozkova, M. Vasylkivska, A. Boufersaoui, B. Marzullo, M. Kolarik, N. Alquezar-Artieda, M. Shaikh, NF. Alaei, M. Zaliova, M. Zwyrtkova, V. Bakardijeva-Mihaylova, M. Alberich-Jorda, J. Trka, DA. Tennant, J. Starkova
520    9_
$a Tumor cells often adapt to amino acid deprivation through metabolic rewiring, compensating for the loss with alternative amino acids/substrates. We have described such a scenario in leukemic cells treated with L-asparaginase (ASNase). Clinical effect of ASNase is based on nutrient stress achieved by its dual enzymatic action which leads to depletion of asparagine and glutamine and is accompanied with elevated aspartate and glutamate concentrations in serum of acute lymphoblastic leukemia patients. We showed that in these limited conditions glutamate uptake compensates for the loss of glutamine availability. Extracellular glutamate flux detection confirms its integration into the TCA cycle and its participation in nucleotide and glutathione synthesis. Importantly, it is glutamate-driven de novo synthesis of glutathione which is the essential metabolic pathway necessary for glutamate's pro-survival effect. In vivo findings support this effect by showing that inhibition of glutamate transporters enhances the therapeutic effect of ASNase. In summary, ASNase induces elevated extracellular glutamate levels under nutrient stress, which leads to a rewiring of intracellular glutamate metabolism and has a negative impact on ASNase treatment.
650    12
$a asparaginasa $x farmakologie $x metabolismus $7 D001215
650    _2
$a lidé $7 D006801
650    12
$a kyselina glutamová $x metabolismus $7 D018698
650    _2
$a zvířata $7 D000818
650    12
$a glutathion $x metabolismus $7 D005978
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x metabolismus $x patologie $7 D054198
650    _2
$a glutamin $x metabolismus $7 D005973
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a citrátový cyklus $x účinky léků $7 D002952
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a myši $7 D051379
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vasylkivska, Maryna $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic
700    1_
$a Boufersaoui, Adam $u Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
700    1_
$a Marzullo, Bryan $u Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
700    1_
$a Kolarik, Matus $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic; First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Alquezar-Artieda, Natividad $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic
700    1_
$a Shaikh, Mehak $u Laboratory of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Alaei, Nadia Fatemeh $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic; Laboratory of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Zaliova, Marketa $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic; University Hospital Motol, Prague, Czech Republic
700    1_
$a Zwyrtkova, Martina $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic
700    1_
$a Bakardijeva-Mihaylova, Violeta $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic
700    1_
$a Alberich-Jorda, Meritxell $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic; Laboratory of Hemato-Oncology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Trka, Jan $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic; University Hospital Motol, Prague, Czech Republic
700    1_
$a Tennant, Daniel A $u Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
700    1_
$a Starkova, Julia $u Childhood Leukaemia Investigation Prague, Prague, Czech Republic; Second Faculty of Medicine, Department of Pediatric Hematology and Oncology, Charles University, Prague, Czech Republic; University Hospital Motol, Prague, Czech Republic. Electronic address: julia.starkova@lfmotol.cuni.cz
773    0_
$w MED00001044 $t Cancer letters $x 1872-7980 $g Roč. 605 (20240911), s. 217242
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39270769 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104308 $b ABA008
999    __
$a ok $b bmc $g 2263260 $s 1239379
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 605 $c - $d 217242 $e 20240911 $i 1872-7980 $m Cancer letters $n Cancer Lett $x MED00001044
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...